Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Papaya Study ID:20140628

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02051634
Recruitment Status : Completed
First Posted : January 31, 2014
Last Update Posted : April 9, 2018
Sponsor:
Collaborator:
Osato Research Institute
Information provided by (Responsible Party):
University of Florida

Brief Summary:
The purpose of this research study is to explore the effects of fermented papaya preparation (FPP) on whole body inflammation, physical function, fatigue, and health-related quality of life. The investigators will conduct a double-blind, randomized, placebo-controlled pilot study on FPP in older adults. If FPP is found to have a beneficial impact on systematic inflammation in this study population (adults aged 70-100 years old), then this supplement may be a potential treatment option to combat aging.

Condition or disease Intervention/treatment Phase
Systemic Inflammation Aging Drug: Fermented Papaya Preparation (FPP) Drug: Sugar Pill Phase 1

Detailed Description:

All of the participants in this research study will be divided randomly into one of two groups: (1) a group taking fermented papaya preparation (FPP) for 8 weeks then taking placebo for 8 weeks or (2) a group taking placebo for 8 weeks then taking FPP for 8 weeks. Placebo sachets do not contain any treatment product. Participants will be assigned randomly to be in one of these two groups.

Participants will be asked to take study product for 8 weeks each, and participation in the study will last for a total of approximately 22 weeks. Participants will be asked to attend five study visits at the University of Florida's Institute on Aging - Clinical & Translational Research Building (IOA - CTRB): Screening Visit, Visit 1, Visit 2, Visit 3, and Visit 4. Visit 1 will take place approximately 30 days after the Screening Visit. Visit 2 will take place approximately 8 weeks after the Screening Visit. Visit 3 will take place approximately 16 weeks after the Screening Visit. Visit 4 will take place approximately 20 weeks after the Screening Visit. Participants will be asked to fast (i.e., no food or liquids except water) for 8 hours prior to all clinic visits. Each visit will take approximately 1.5 to 2 hours.

Participants will also be called weekly during the study to ask how they are feel and to find out and if they remembered to take all of their study product. Finally, investigators will call approximately two weeks after participants stop taking the study product to ask how they are feeling.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Efficacy of Fermented Papaya Preparation on Markers of Systemic Inflammation
Study Start Date : October 2014
Actual Primary Completion Date : December 2016
Actual Study Completion Date : December 2016

Arm Intervention/treatment
Active Comparator: Fermented Papaya Preparation (FPP)
A total of 9 grams of FPP per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing FPP per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner. Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.
Drug: Fermented Papaya Preparation (FPP)
A total of 9 grams of FPP per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing FPP per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner. Participants will open the sachet, slowly empty contents into their mouth, and let it dissolve before swallowing.
Other Name: Papaya

Drug: Sugar Pill
A total of 9 grams of placebo (sugar) per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing placebo per day - once with breakfast, once with lunch, and once with dinner. Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.

Placebo Comparator: Sugar Pill
A total of 9 grams of placebo (sugar) per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing placebo per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner. Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.
Drug: Fermented Papaya Preparation (FPP)
A total of 9 grams of FPP per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing FPP per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner. Participants will open the sachet, slowly empty contents into their mouth, and let it dissolve before swallowing.
Other Name: Papaya

Drug: Sugar Pill
A total of 9 grams of placebo (sugar) per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing placebo per day - once with breakfast, once with lunch, and once with dinner. Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.




Primary Outcome Measures :
  1. Interleukin-6 (IL-6) will be tested at weeks 8 and 20 [ Time Frame: Change from 8 weeks and 20 weeks ]
    Blood test performed.

  2. Tumor necrosis factor-α (TNF-α) will be tested at weeks 8 and 20 [ Time Frame: Change from 8 weeks and 20 weeks ]
    Blood test will be performed.

  3. C - reactive protein (CRP) will be tested at weeks 8 and 20 [ Time Frame: Change from 8 weeks and 20 weeks ]
    Blood test will be performed.

  4. Myeloperoxidase (MPO) will be tested at weeks 8 and 20 [ Time Frame: Change from 8 weeks and 20 weeks ]
    Blood test will be performed.


Secondary Outcome Measures :
  1. Short Physical Performance Battery [ Time Frame: Change from 8 weeks and 20 weeks ]
    Physical function test to assess functional performance on different tasks including timed short distance walk, repeated chair stands, and a balance test.

  2. 6 Minute Walk Test performed at weeks 8 and 20. [ Time Frame: Change from 8 weeks and 20 weeks ]
    The 6 Minute Walk tests functional walking endurance. Participants will be asked to walk at a comfortable pace for 6 minutes. Total distance completed, blood pressure, and pulse rate will be measured.

  3. Health-related quality of life performed at weeks 8 and 20 [ Time Frame: Change from 8 weeks and 20 weeks ]
    RAND SF-36 Short Form Health Survey (SF-36) measures eight domains: physical functioning, role limitations due to physical health, role limitations due to emotional problems, vitality (energy/fatigue), emotional well being, bodily pain, social functioning, and general health perceptions.

  4. Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) performed at weeks 8 and 20 [ Time Frame: Change from 8 weeks and 20 weeks ]
    FACIT-Fatigue is a measure of physical and functional consequences of fatigue, with lower scores indicating more fatigue.

  5. Brief Fatigue Symptom Inventory (FSI) [ Time Frame: Change from 8 weeks and 20 weeks ]
    FSI is a measure of physical and functional consequences of fatigue.

  6. Superoxide dismutases (SOD) tested at weeks 8 and 20. [ Time Frame: Change from 8 weeks and 20 weeks ]
    Blood test will be performed.

  7. Glutathione Peroxidase tested at weeks 8 and 20. [ Time Frame: Change from 8 weeks and 20 weeks ]
    Blood test will be performed.

  8. Total Antioxidant Capacity will be tested at weeks 8 and 20 [ Time Frame: Change from 8 weeks and 20 weeks ]
    Blood test will be performed.

  9. Muscle tissue oxygenation tested at weeks 8 and 20 [ Time Frame: Change from 8 weeks and 20 weeks ]
    Participants will be asked to perform a leg extension endurance exercise with electrodes placed on their forehead and thigh.

  10. Brain tissue oxygenation tested at weeks 8 and 20 [ Time Frame: Change from 8 weeks and 20 weeks ]
    Participants will complete a series of memory and thinking tasks while wearing electrodes on their head. The N-Back Test that measures working memory will be conducted for 10 minutes.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   70 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Body mass index > 25 and < 40 kg/m2;
  • Willing and able to participate in all aspects of the study;
  • Self-reported sedentary to moderately active lifestyle (<120 min aerobic activity/week);
  • Self-reported ability to walk ¼ mile without the use of an assistive device (i.e., cane, walker, crutch);
  • Mild to Moderate physical impairment (SPPB score 4-10);
  • Not confined to a wheelchair;
  • Mini Mental Status Exam score > 24;
  • Able to swallow study product as directed.

Exclusion Criteria:

  • Failure to give consent;
  • Active treatment for cancer (< 3 years);
  • Stroke (< 6 mo);
  • Serious heart condition, peripheral vascular disease, coronary artery disease (myocardial infarction<6 mo), Class III, IV Congestive Heart Failure;
  • Severe anemia (Hgb < 8.0 g/dL);
  • Liver or renal disease;
  • Diabetes;
  • Severe osteoarthritis;
  • Fracture in upper or lower extremity within the last 6 months;
  • Upper or lower extremity amputation;
  • Anticoagulant therapy (aspirin use is permitted);
  • Parkinson's disease;
  • Severe psychiatric disease or psychological disorder (e.g., severe depression, bi-polar disorder, schizophrenia) or current use of antipsychotics;
  • Current use of anabolic medications (e.g., growth hormone or testosterone) or anticholinesterase inhibitor (i.e., Aricept);
  • High amounts of physical activity (i.e., running, bicycling, etc.) > 120 min/week;
  • Excessive alcohol use (>2 drinks per day);
  • Use of tobacco products;
  • Resting heart rate > 120 bpm;
  • Blood pressure with Systolic > 160mmHg and Diastolic >90mmHg;
  • History of significant head injury leading to cognitive impairments;
  • Visual or hearing impairments that would interfere with testing;
  • Current consumption of any dietary supplements containing resveratrol, quercetin, or P. cuspidatum, grape seed extract, or ginko biloba;
  • Allergies to papaya or foods with similar compounds (i.e., banana, avocado, kiwi, chestnuts, hazel nuts)
  • Allergy to latex;
  • Participating in another clinical trial or has received an investigational product within 30 days prior to screening/enrollment;
  • Center for Epidemiological Studies - Depression Scale (CES-D) Score > 20.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02051634


Locations
Layout table for location information
United States, Florida
University of Florida
Gainesville, Florida, United States, 32611
Sponsors and Collaborators
University of Florida
Osato Research Institute
Investigators
Layout table for investigator information
Principal Investigator: Stephen D Anton, PhD University of Florida
Layout table for additonal information
Responsible Party: University of Florida
ClinicalTrials.gov Identifier: NCT02051634    
Other Study ID Numbers: IRB20140628
First Posted: January 31, 2014    Key Record Dates
Last Update Posted: April 9, 2018
Last Verified: April 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Florida:
Aging
Papaya
Fermented Papaya
Inflammation
Phytochemicals
Physical function
Quality of life
Fatigue
Health
Additional relevant MeSH terms:
Layout table for MeSH terms
Inflammation
Pathologic Processes